Urinary prednisolone excretion is a determinant of serum hepcidin levels in renal transplant recipients
To the Editor:
Hepcidin, which is synthesized and secreted by the liver, is considered the master regulator of iron homeostasis. Hepcidin regulates the amount of iron absorbed from the intestines and the iron release from the reticuloendothelial system by degrading ferroportin, the iron transporter located at the duodenal enterocytes and macrophages.
Circulating levels of hepcidin are known to be controlled by available iron stores, inflammation, hypoxia, insulin levels, and erythropoiesis. Here, we report on the association of serum hepcidin with 24-h urinary prednisolone excretion, as a measure of 24-h prednisolone exposure.
For this study, 606 stable RTRs with a functioning graft beyond the first year after transplantation were included. 4 All RTRs gave written informed consent for the study and approval by institutional review (Table 1) .
In univariate regression analysis, serum hepcidin was found to be negatively associated with 24-h urinary prednisolone excretion In this study, we show that 24-h urinary prednisolone excretion is negatively associated with serum hepcidin in RTRs irrespective of potential confounders, including eGFR. All RTRs in our cohort used a low dose eGFR, estimated glomerular filtration rate; EPO, erythropoietin; hs-CRP, high sensitivity C-reactive protein.
E174 | prednisolone (5-10 mg/day). Remarkably, this resulted in a broad range of 24-h urinary prednisolone excretion and a modest association with the daily prednisolone dose, in keeping with considerable inter-subject pharmacokinetic variability. 5 Twenty-4 h urinary prednisolone excretion is considered to reflect the overall exposure to prednisolone. Previously, it has been shown that prednisolone dose-dependently inhibits the release of interleukin-6 (IL-6) 6 which is known to induce hepcidin expression. We had no data available on IL-6 levels to assess whether effects on IL-6 is the mechanism behind the association of prednisolone with hepcidin. The possible role of prednisolone as a direct hepcidin antagonist and possible mechanisms linking prednisolone with hepcidin need to be delineated in more detail in future studies.
The major strength of this report is the large cohort of RTRs with availability of concurrent 24-h urinary prednisolone excretion and hepcidin data. Limitations are that it comprises a single center study, and that we cannot exclude the possibility of residual confounding.
In conclusion, lower serum hepcidin levels are related to higher TP53 is a tumor suppressor gene that has been studied extensively in MDS and AML, in which the mutations are associated with a complex karyotype and a poor prognosis. Its mutations also occur in CHIP and CCUS. 2, 3 The characteristics of TP53 mutations and their role in disease progression in these pre-MDS conditions are unknown.
In this study, we aim to characterize the clinicopathological features of CCUS cases associated with TP53 mutations. 
